Merrimack Pharmaceuticals Inc.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Apr 2011 | $77 M | No. 1 | $50 to $250 million | equity | SEC |
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Merrimack Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2011).
SEC Form D · Apr 2011
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Apr 2011
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Merrimack Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Robert J. Mulroy | Executive officer | Apr 2011 |
| William A. Sullivan | Executive officer | Apr 2011 |
| Anthony A. Sinskey | Director | Apr 2011 |
| Gary A. Crocker | Director | Apr 2011 |
| Gordon A. Fehr | Director | Apr 2011 |
| James A. Dresser | Director | Apr 2011 |
| Michael A. Porter | Director | Apr 2011 |
| Robert A. Gay | Director | Apr 2011 |
| Robert J. Mulroy | Director | Apr 2011 |
| Sarah A. Nash | Director | Apr 2011 |
| Walter A. Lovenberg | Director | Apr 2011 |